Aurealis Therapeutics, a synthetic biology company developing cell and gene therapies, has raised CHF 8 million from existing investors and shareholders. The funds will be primarily used to complete Phase 2 clinical studies with Aurealis lead product AUP-16 for Chronic Wounds and accelerate the preclinical and CMC development of the lead candidate AUP-55 for cancers..

Aurealis Therapeutics是一家开发细胞和基因疗法的合成生物学公司，已从现有投资者和股东那里筹集了800万瑞士法郎。这些资金将主要用于完成Aurealis铅产品AUP-16治疗慢性伤口的2期临床研究，并加速癌症主要候选AUP-55的临床前和CMC开发。

Aurealis’ cell and gene therapies allow to modulate tissue microenvironment and tackle complex multi-factorial diseases such as chronic wounds, cancers, and inflammation. Aurealis modular gene therapy platform consists of non-pathogenic lactic acid bacterium Lactococcus cremoris, genetically engineered to produce and release multiple human therapeutic proteins in the body: cytokines, chemokines, growth factors, antibody fragments.

金黄色葡萄球菌的细胞和基因疗法可以调节组织微环境，并解决复杂的多因素疾病，如慢性伤口，癌症和炎症。

These living bacterium act as millions of nanoscale bioreactors at the site of the disease, allowing multi-targeting as one product, to treat multifactorial diseases. Aurealis pipeline includes Chronic Wounds (AUP-16, ongoing Phase 2), Oncology (AUP-55, pre-clinical stage), Inflammation (AUP-60, discovery stage)..

这些活细菌在疾病部位充当数百万纳米级生物反应器，允许多靶向作为一种产品来治疗多因素疾病。金黄色葡萄球菌管道包括慢性伤口（AUP-16，正在进行的第二阶段），肿瘤学（AUP-55，临床前阶段），炎症（AUP-60，发现阶段）。

The Swiss-Finish company raised CHF 8 million from existing investors and shareholders. The funds will be primarily used to complete Phase 2 clinical studies with AUP-16 for Chronic Wounds, such as Diabetic Foot Ulcer (DFU), and accelerate the preclinical and CMC development of the lead candidate AUP-55 for cancers such as ovarian cancer, other peritoneal carcinomatosis and bladder cancer..

这家瑞士Finish公司从现有投资者和股东那里筹集了800万瑞士法郎。这些资金将主要用于完成AUP-16治疗糖尿病足溃疡（DFU）等慢性伤口的2期临床研究，并加速主要候选AUP-55治疗卵巢癌、其他腹膜癌病和膀胱癌等癌症的临床前和CMC开发。

“We are excited to announce this successful funding round and want to express our gratitude for the trust and support that we have received from the investors. We have exciting times ahead as our Phase 2 study in Diabetic Foot Ulcer is close to completion, and our oncology program is moving towards the clinic” said Juha Yrjänheikki, CEO of Aurealis Therapeutics..

Aurealis Therapeutics首席执行官Juha Yrjänheikki说：“我们很高兴宣布这一成功的融资回合，并感谢投资者对我们的信任和支持。随着我们对糖尿病足溃疡的第二阶段研究接近完成，我们的肿瘤学计划正在走向诊所，我们还有令人兴奋的时刻。”

“We have successfully developed our platform and key assets AUP-16 for Chronic Wounds and AUP-55 for Cancer. Positive clinical data, existing and new partnerships, and growing investor base and interest at the market makes us highly confident about completing our next CHF 35M equity round and creating substantial value to all stakeholders” continued Laurent Décory, COO of Aurealis Therapeutics..

“我们已经成功开发了针对慢性伤口的平台和关键资产AUP-16以及针对癌症的AUP-55。积极的临床数据、现有和新的合作伙伴关系以及不断增长的投资者基础和市场兴趣，使我们对完成下一轮3500万瑞士法郎的股权投资充满信心，并为所有利益相关者创造了巨大的价值。”Aurealis Therapeutics首席运营官Laurent Décory继续说道。

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送